{
  "extraction_metadata": {
    "timestamp": "2025-10-01T11:36:52.119257",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "progression-free survival (blinded independent central review), overall survival (time from randomisation to death from any cause), symptomatology (patient-reported), health status (patient-reported), EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, EQ-5D visual analogue scale (EQ-5D VAS), adverse events (AEs), serious adverse events (SAEs), severe adverse events, discontinuation due to adverse events, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE), PRO-CTCAE (patient-reported outcome version of the Common Terminology Criteria for Adverse Events; instrument used for side effects)",
      "ChunksUsed": 35,
      "ContextTokens": 8006
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (RECIST v1.1), event-free survival, time to progression (TTP), time to next treatment (TTNT), objective response rate (ORR), disease control rate, duration of response (DoR), time to response, treatment duration, treatment discontinuation due to adverse events, adverse events (CTCAE v5.0), adverse events (CTCAE v4.03), grade 3 or higher adverse events, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, NSCLC-SAQ, PGIS, PGIC, PRO-CTCAE, item GP5 of the FACT-G, changes in cancer-specific symptoms, changes in overall health status, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 35,
      "ContextTokens": 8857
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), objective response rate (ORR; RECIST 1.1; blinded independent central review), complete response (RECIST 1.1), partial response (RECIST 1.1), health-related quality of life, visual analogue scale (progression-free health state), utility values (time-to-death approach), utility values (health-state approach), disutility associated with intravenous administration, dose modifications, adverse events (general), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 35,
      "ContextTokens": 6883
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "progression-free survival (independent review committee, RECIST 1.1), progression-free survival (RECIST 1.1), overall survival, objective response rate (independent review committee, RECIST 1.1), duration of response (RECIST 1.1), disease control rate, time to response, adverse events (general), serious adverse events, EORTC QLQ-C30, EORTC QLQ-LC13",
      "ChunksUsed": 35,
      "ContextTokens": 7545
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "",
      "ChunksUsed": 6,
      "ContextTokens": 1644
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), quality of life (EORTC QLQ-C30), quality of life (EORTC QLQ-LC13), anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity, increased ALT, increased AST, weight loss, oral cavity blockage, asthenia, neutropenia, peripheral neuropathy, alopecia, decreased appetite, chest pain, treatment-related adverse events (general), serious adverse events (SAEs), treatment-related adverse events leading to discontinuation, treatment-related adverse events grade â‰¥ 3, treatment-associated adverse events resulting in death, economic outcome (quality-adjusted life years, QALYs), economic outcome (cost-effectiveness, incremental cost-effectiveness ratio, ICER), economic outcome (life years gained, LYG)",
      "ChunksUsed": 33,
      "ContextTokens": 7056
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS; RECIST v1.1), event-free survival, time to progression, time to next treatment, response rate, objective response rate (ORR), duration of response (DoR), disease control rate, duration of treatment, dropout rate, adverse event rate, serious adverse event rate, grade 3-4 adverse event rate, mortality-related toxicity, adverse events (CTCAE v5.0), diarrhoea, nausea, fatigue, neutropenia, anaemia, headache, chest pain, dyspnoea, cough, physical functioning deterioration, overall health status deterioration, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, visual analogue scale (EQ-5D-5L), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 35,
      "ContextTokens": 8692
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "progression-free survival (PFS), overall survival (OS), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY), health-related quality of life (measured by time to death)",
      "ChunksUsed": 34,
      "ContextTokens": 5854
    }
  }
}